NC
KYMR icon

nVerses Capital’s Kymera Therapeutics KYMR Stock Holding History

nVerses Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$4.73K – 463
2024
Q3 		$4.73K Buy
+100
New +$4.42K ﹤0.01% 934

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

nVerses Capital's KYMR Position: Q4 2024 in Review

nVerses Capital sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 100 shares — an estimated $4.73K sold.

nVerses Capital first reported a position in KYMR in Q3 2024 and held it in 1 quarter. The position peaked at $4.73K in Q3 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • nVerses Capital reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 100 Kymera Therapeutics shares in Q4 2024, an estimated $4.73K.
  • nVerses Capital first reported a position in Kymera Therapeutics in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Kymera Therapeutics position peaked at $4.73K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.